WP
AKBA icon

Woodline Partners’s Akebia Therapeutics AKBA Stock Holding History

Woodline Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,001,360
Closed -$3.64M – 875
2025
Q2 		$3.64M Sell
1,001,360
-1,484,218
-60% -$4.08M 0.02% 618
2025
Q1 		$4.77M Buy
+2,485,578
New +$5.07M 0.03% 521
2022
Q1 		– Sell
-2,231,966
Closed -$5.04M – 716
2021
Q4 		$5.04M Sell
2,231,966
-91,551
-4% -$250K 0.07% 280
2021
Q3 		$6.69M Buy
2,323,517
+2,199,743
+1,777% +$6.28M 0.11% 217
2021
Q2 		$469K Buy
+123,774
New +$417K 0.01% 476
2021
Q1 		– Sell
-2,382,522
Closed -$6.67M – 428
2020
Q4 		$6.67M Sell
2,382,522
-3,076,414
-56% -$8.98M 0.18% 141
2020
Q3 		$13.7M Buy
5,458,936
+4,814,707
+747% +$42.3M 0.45% 65
2020
Q2 		$8.75M Buy
644,229
+17,519
+3% +$181K 0.35% 80
2020
Q1 		$4.75M Sell
626,710
-646,077
-51% -$5.03M 0.34% 88
2019
Q4 		$8.04M Buy
+1,272,787
New +$6.05M 0.33% 76

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Woodline Partners's AKBA Position: Q3 2025 in Review

Woodline Partners sold out of Akebia Therapeutics (AKBA) in Q3 2025, closing a stake of 1,001,360 shares — an estimated $3.64M sold.

Woodline Partners first reported a position in AKBA in Q4 2019 and held it in 10 quarters. The position peaked at $13.7M in Q3 2020. 177 funds tracked by Wall St. Rank hold AKBA as of Q3 2025.

  • Woodline Partners reported no remaining Akebia Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Woodline Partners sold 1,001,360 Akebia Therapeutics shares in Q3 2025, an estimated $3.64M.
  • Woodline Partners first reported a position in Akebia Therapeutics in Q4 2019 and held it in 10 quarters.
  • Woodline Partners's Akebia Therapeutics position peaked at $13.7M in Q3 2020.
  • 177 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2025.

Based on Woodline Partners's 13F filing for Q3 2025, filed 14 Nov 2025.